Lipid-Lowering Agents - Sudan

Sudan

The revenue in the Sudanese market for Lipid-Lowering Agents market is estimated to reach US$0.43m in 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of -1.93%, leading to a market volume of US$0.39m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$4,461.00m in 2024.
In Sudan, the demand for lipid-lowering agents is steadily increasing due to the rising prevalence of cardiovascular diseases in the country.

Key regions: Europe, Brazil, France, Australia, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The Lipid-Lowering Agents market in Sudan has seen significant growth in recent years.

Customer preferences: Customers in Sudan are increasingly concerned about their health and are seeking ways to prevent and manage chronic diseases such as cardiovascular disease. As a result, there has been a growing demand for Lipid-Lowering Agents, which are used to reduce cholesterol levels in the blood and lower the risk of heart disease.

Trends in the market: The Lipid-Lowering Agents market in Sudan has been growing steadily due to the increasing prevalence of cardiovascular disease in the country. The market is dominated by statins, which are the most commonly prescribed Lipid-Lowering Agents. However, there has been a growing trend towards the use of combination therapies, which combine two or more drugs to achieve better cholesterol-lowering effects. This trend is expected to continue as healthcare providers in Sudan become more aware of the benefits of combination therapy.

Local special circumstances: The healthcare system in Sudan is underdeveloped, and access to healthcare services is limited, particularly in rural areas. As a result, many people in Sudan have limited access to Lipid-Lowering Agents and other essential medicines. However, the government has been taking steps to improve access to healthcare services and medicines, which is expected to drive growth in the Lipid-Lowering Agents market in the coming years.

Underlying macroeconomic factors: Sudan has a rapidly growing population, which is expected to increase demand for healthcare services and medicines, including Lipid-Lowering Agents. The country is also experiencing economic growth, which is expected to drive up household incomes and increase demand for healthcare products. However, the political situation in Sudan remains uncertain, which could impact the growth of the Lipid-Lowering Agents market and the healthcare sector more broadly.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.